Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

S-CKD602 is a PEGylated liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. The objective of this study was to characterize the bidirectional pharmacokinetic–pharmacodynamic (PK–PD) interaction between S-CKD602 and monocytes. Plasma concentrations of encapsulated CKD-602 and monocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Huali, Ramanathan, Ramesh K, Zamboni, Beth A, Strychor, Sandra, Ramalingam, Suresh, Edwards, Robert P, Friedland, David M, Stoller, Ronald G, Belani, Chandra P, Maruca, Lauren J, Bang, Yung-Jue, Zamboni, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480239/
https://www.ncbi.nlm.nih.gov/pubmed/23112576
http://dx.doi.org/10.2147/IJN.S35751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480239/
https://www.ncbi.nlm.nih.gov/pubmed/23112576
http://dx.doi.org/10.2147/IJN.S35751

Ejemplares similares